Cancer Genetics (CGIX) Sees IPO Price in $11-$13/Share Range

In an amended S-1 filing from Monday morning, Cancer Genetics (Nasdaq: CGIX) disclosed it expects to price 4 million shares of its common stock in the range of $11-$13 per share. The company plans to list on the NASDAQ exchange under the symbol "CGIX."

The offering is being made through Needham & Company and First Analysis Securities.

Cancer Genetics is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed target cancers that are difficult to prognose and predict treatment outcomes by using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• CopperTech Metals launches IPO roadshow on NYSE at $16-$18 per share
• Kardigan raises $460M in IPO on Nasdaq
• Doncasters Group guiding IPO pricing at top of range - Bloomberg